New drug combo targets tough cancers in early trial

NCT ID NCT05929235

Ongoing Disease control Sponsor: Flare Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This early-stage study tests a new oral drug, FX-909, alone or with another drug (pembrolizumab) in people with advanced solid tumors, including a type of bladder cancer. The main goals are to check safety and find the best dose. About 120 adults will take part, taking daily pills and visiting the clinic for tests and scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED UROTHELIAL CARCINOMA OPEN LABEL ORAL DRUG ADMINISTRATION

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Houston Methodist Cockrell Center for Advanced Therapeutics

Houston, Texas, 77030, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Mass General Cancer Center

Boston, Massachusetts, 02114, United States
Memorial Slone Kettering Cancer Center

New York, New York, 10065, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sylvester Comprehensive Cancer Center, University of Miami

Miami, Florida, 33136, United States
The Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
The University of Chicago Medicine

Chicago, Illinois, 60637, United States
UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94158, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27514, United States
Yale Cancer Center

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.